<span item_type="fundamental" item_id="2ba33e4df53830537475d0ff80e8d016" counter_id="ST/US/OTLK" env="prod"></span><span item_type="announcement" item_id="595365830366600065" env="prod"></span><p>Revenue: As of FY2025, the actual value is USD 1.413 M.</p><p>EPS: As of FY2025, the actual value is USD -1.79, missing the estimate of USD -1.6425.</p><p>EBIT: As of FY2025, the actual value is USD -66.87 M.</p><p></p><h3>Financial Highlights for Fiscal Year 2025</h3><h4>Revenue</h4><ul><li>Outlook Therapeutics reported $1.4 million in revenue for the fiscal year ended September 30, 2025, compared to no revenue in the prior year. This revenue was primarily from initial sales of LYTENAVA™ in Germany and the UK.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/tm2533934d1_ex99-1.htm"></span></li></ul><h4>Net Loss</h4><ul><li>The net loss attributable to common stockholders was $62.4 million, or $1.79 per basic and diluted share, compared to a net loss of $75.4 million, or $4.06 per share, in the previous year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/tm2533934d1_ex99-1.htm"></span></li></ul><h4>Gross Profit</h4><ul><li>Gross profit for fiscal 2025 was $57,000, negatively impacted by increased reserves for short-dated inventory included in the original shipments to the UK.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/tm2533934d1_ex99-1.htm"></span></li></ul><h4>Operating Expenses</h4><ul><li>Total operating expenses decreased by $4.6 million compared to fiscal 2024, primarily due to a reduction in R&amp;D expenses following the completion of the NORSE Eight clinical trial. However, SG&amp;A expenses increased due to the launch of LYTENAVA™ in Europe.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/tm2533934d1_ex99-1.htm"></span></li></ul><h4>Cash and Cash Equivalents</h4><ul><li>As of September 30, 2025, cash and cash equivalents were $8.1 million, not including $14.9 million of net proceeds from sales under its at-the-market offering program after September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/tm2533934d1_ex99-1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Outlook Therapeutics is preparing for potential FDA approval and commercial launch activities in the U.S., with a PDUFA goal date for ONS-5010 set for December 31, 2025. The company is also expanding its market presence in Europe, with plans to launch in Austria and the Netherlands, and is seeking additional partners for further expansion outside the U.S.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/tm2533934d1_ex99-1.htm"></span></li></ul>

Outlook Therapeutics | 8-K: FY2025 Revenue: USD 1.413 M